Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Goserelin
Drug ID BADD_D01038
Description Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Indications and Usage Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
Marketing Status Prescription
ATC Code L02AE03
DrugBank ID DB00014
KEGG ID D04405
MeSH ID D017273
PubChem ID 5311128
TTD Drug ID D00BCG
NDC Product Code 70720-951; 55463-0005; 70720-950
Synonyms Goserelin | ICI-118630 | ICI 118630 | ICI118630 | Zoladex | Goserelin Acetate | Acetate, Goserelin
Chemical Information
Molecular Formula C59H84N18O14
CAS Registry Number 65807-02-5
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C( CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C 6CCC(=O)N6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.002206%
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Uterine leiomyoma21.07.02.004; 16.04.02.0010.003677%Not Available
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.002206%
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Varicose vein24.10.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.003--
Vulvovaginitis21.14.02.005; 11.01.10.003--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.0060.002942%
Peripheral swelling08.01.03.053; 02.05.04.0150.002206%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.016--Not Available
Abasia17.02.05.035; 08.01.02.0070.001471%Not Available
Bone density decreased13.16.01.001--Not Available
Pituitary haemorrhage24.07.04.009; 17.08.01.019; 05.03.04.0050.001471%Not Available
Balance disorder17.02.02.0070.001471%Not Available
Abulia19.01.02.009; 17.02.05.0400.001471%Not Available
Dysstasia17.02.02.0120.001471%Not Available
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.004--Not Available
Deep vein thrombosis24.01.02.0030.002942%Not Available
Malignant neoplasm progression16.16.01.0050.012471%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal stiffness15.03.01.0050.001471%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Nodule08.03.05.002--Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages